Firma Immunic, Autor bei News-Research

Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity

6. August 202113. Dezember 2023 Firma ImmunicPosted in Finanzen / BilanzenTagged 4sc, caldose, cancer, gtthe, immunic, imu, ltem, ltli, ltp, ltstrong, ltul, quotdisc, rrms, thymocyte, with

– Received FDA Clearance to Initiate Twin IMU-838 Phase 3 ENSURE Trials in Relapsing-Remitting Multiple Sclerosis and Supportive Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis – – Reported In […]

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

20. Juli 202113. Dezember 2023 Firma ImmunicPosted in Finanzen / BilanzenTagged aegis, clinical, financial, fiscal, immunic, immunic's, imu, prospectus, report, revenue, roth, sandler, securities, statements, with

Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of […]

Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock

15. Juli 202113. Dezember 2023 Firma ImmunicPosted in Finanzen / BilanzenTagged aegis, clinical, financial, fiscal, immunic, immunic's, imu, prospectus, report, revenue, roth, sandler, securities, statements, with

Immunic, Inc. Announces Proposed Public Offering of Common Stock

15. Juli 202113. Dezember 2023 Firma ImmunicPosted in Finanzen / BilanzenTagged clinical, financial, fiscal, immunic, immunic's, imu, market, prospectus, report, revenue, risks, sandler, securities, statements, with

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

1. Juli 202113. Dezember 2023 Firma ImmunicPosted in Forschung und EntwicklungTagged brain, calvid, dosing, immunic, immunic's, imu, market, neurofilament, patients, ppms, revenue, rrms, statements, unblinded, with

. – Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo, Intended to Provide Straightforward Path to Regulatory […]

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel

1. Juni 202113. Dezember 2023 Firma ImmunicPosted in Forschung und EntwicklungTagged clinical, fiscal, immunic, immunic's, imu, market, mba, merck, new, project, report, revenue, securities, statements, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as […]

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity

6. Mai 202113. Dezember 2023 Firma ImmunicPosted in Finanzen / BilanzenTagged 4sc, caldose, calvid, fiscal, immunic, immunic's, imu, market, patients, revenue, rrms, statements, unblinded, vaccines, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended […]

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838

31. März 202113. Dezember 2023 Firma ImmunicPosted in BiotechnikTagged 4sc, cancer, domatinostat, fiscal, immunic, immunic's, imu, market, revenue, Royalties, rrms, securities, statements, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime Standard: VSC), […]

Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity

26. Februar 202113. Dezember 2023 Firma ImmunicPosted in Forschung und EntwicklungTagged caldose, calvid, dosing, immunic, immunic's, imu, liver, market, patients, revenue, rrms, statements, syndrome, unblinded, with

Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to Begin in the Second Half of 2021 Reported Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of […]

Immunic, Inc. Added to NASDAQ Biotechnology Index

14. Dezember 202013. Dezember 2023 Firma ImmunicPosted in Forschung und EntwicklungTagged clinical, etf, etfs, fiscal, ibb, immunic, immunic's, imu, index, ishares, market, revenue, securities, statements, with